South American haemorrhagic fevers

References

Key articles

Patterson M, Grant A, Paessler S. Epidemiology and pathogenesis of Bolivian hemorrhagic fever. Curr Opin Virol. 2014;5:82-90.Full text  Abstract

Gómez RM, Jaquenod de Giusti C, Sanchez Vallduvi MM, et al. Junín virus. A XXI century update. Microbes Infect. 2011;13:303-311. Abstract

Enria DA, Briggiler AM, Sánchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 2008;78:132-139. Abstract

Enria DA, Briggiler AM, Feuillade MR. An overview of the epidemiological, ecological and preventive hallmarks of Argentine haemorrhagic fever (Junin virus). Bulletin Institut Pasteur. 1998;96:103-114.

de Manzione N, Salas RA, Paredes H, et al. Venezuelan hemorrhagic fever: clinical and epidemiological studies of 165 cases. Clin Infect Dis. 1998;26:308-313.Full text  Abstract

Delgado S, Erickson BR, Agudo R, et al. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog. 2008;4:e1000047.Full text  Abstract

Grant A, Seregin A, Huang C, et al. Junín virus pathogenesis and virus replication. Viruses. 2012;4:2317-2339.Full text  Abstract

Reference articles

1. Patterson M, Grant A, Paessler S. Epidemiology and pathogenesis of Bolivian hemorrhagic fever. Curr Opin Virol. 2014;5:82-90.Full text  Abstract

2. Gómez RM, Jaquenod de Giusti C, Sanchez Vallduvi MM, et al. Junín virus. A XXI century update. Microbes Infect. 2011;13:303-311. Abstract

3. Enria DA, Briggiler AM, Sánchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 2008;78:132-139. Abstract

4. Enria DA, Briggiler AM, Feuillade MR. An overview of the epidemiological, ecological and preventive hallmarks of Argentine haemorrhagic fever (Junin virus). Bulletin Institut Pasteur. 1998;96:103-114.

5. de Manzione N, Salas RA, Paredes H, et al. Venezuelan hemorrhagic fever: clinical and epidemiological studies of 165 cases. Clin Infect Dis. 1998;26:308-313.Full text  Abstract

6. Delgado S, Erickson BR, Agudo R, et al. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog. 2008;4:e1000047.Full text  Abstract

7. Barry M, Russi M, Armstrong L, et al. Brief report: treatment of a laboratory-acquired Sabiá virus infection. N Engl J Med. 1995;333:294-296.Full text  Abstract

8. Centers for Disease Control and Prevention. Viral hemorrhagic fevers (VHFs): Old World/New World arenaviruses. June 2013 [internet publication].Full text

9. Grant A, Seregin A, Huang C, et al. Junín virus pathogenesis and virus replication. Viruses. 2012;4:2317-2339.Full text  Abstract

10. Centers for Disease Control and Prevention. Viral hemorrhagic fevers (VHFs): arenaviridae. June 2013 [internet publication].Full text

11. Mackenzie RB. Epidemiology of Machupo virus infection. I. Pattern of human infection, San Joaquín, Bolivia, 1962-1964. Am J Trop Med Hyg. 1965;14:808-813. Abstract

12. Garrett L. The coming plague: newly emerging diseases in a world out of balance. New York, NY: Farrar, Straus and Giroux; 1994.

13. Escalera-Antezana JP, Rodriguez-Villena OJ, Arancibia-Alba AW, et al. Clinical features of fatal cases of Chapare virus hemorrhagic fever originating from rural La Paz, Bolivia, 2019: A cluster analysis. Travel Med Infect Dis. 2020 Jul - Aug;36:101589. Abstract

14. Fulhorst CF, Bowen MD, Salas RA, et al. Natural rodent host associations of Guanarito and pirital viruses (Family Arenaviridae) in central Venezuela. Am J Trop Med Hyg. 1999;61:325-330.Full text  Abstract

15. Abraham J, Corbett KD, Farzan M, et al. Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses. Nat Struct Mol Biol. 2010;17:438-444.Full text  Abstract

16. Zinzula L, Tramontano E. Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: hide, mask, hit. Antiviral Res. 2013;100:615-635. Abstract

17. Xing J, Ly H, Liang Y. The Z proteins of pathogenic but not nonpathogenic arenaviruses inhibit RIG-I-like receptor-dependent interferon production. J Virol. 2015;89:2944-2955.Full text  Abstract

18. Fan L, Briese T, Lipkin WI. Z proteins of new world arenaviruses bind RIG-I and interfere with type I interferon induction. J Virol. 2010;84:1785-1791.Full text  Abstract

19. Marta RF, Montero VS, Hack CE, et al. Proinflammatory cytokines and elastase-alpha-1-antitrypsin in Argentine hemorrhagic fever. Am J Trop Med Hyg. 1999;60:85-89.Full text  Abstract

20. World Health Organization. Guidance: steps to remove personal protective equipment. 2014 [internet publication].Full text

21. World Health Organization. Guidance: steps to put on personal protective equipment. 2014 [internet publication].Full text

22. Centers for Disease Control and Prevention. Guidance on personal protective equipment (PPE) to be used by healthcare workers during management of patients with confirmed Ebola or persons under investigation (PUIs) for Ebola who are clinically unstable or have bleeding, vomiting, or diarrhea in US hospitals, including procedures for donning and doffing PPE. August 2018 [internet publication].Full text

23. UK Department of Health. Management of Hazard Group 4 viral haemorrhagic fevers and similar human infectious diseases of high consequence. November 2015 [internet publication].Full text

24. Olschläger S, Flatz L. Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials. PLoS Pathog. 2013;9:e1003212.Full text  Abstract

25. Kerber R, Reindl S, Romanowski V, et al. Research efforts to control highly pathogenic arenaviruses: a summary of the progress and gaps. J Clin Virol. 2015;64:120-127. Abstract

26. Leligdowicz A, Fischer WA 2nd, Uyeki TM, et al. Ebola virus disease and critical illness. Crit Care. 2016;20:217. Abstract

27. Enria D, Mills JN, Bausch D, et al. Arenavirus infections. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens, and practice. 3rd ed. Amsterdam: Elsevier; 2011:449-461.

28. Salazar M, Yun NE, Poussard AL, et al. Effect of ribavirin on Junin virus infection in guinea pigs. Zoonoses Public Health. 2012;59:278-285. Abstract

29. Kilgore PE, Ksiazek TG, Rollin PE, et al. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis. 1997;24:718-722.Full text  Abstract

30. Mendenhall M, Russell A, Juelich T, et al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother. 2011;55:782-787.Full text  Abstract

31. Gowen BB, Juelich TL, Sefing EJ, et al. Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. PLoS Negl Trop Dis. 2013;7:e2614.Full text  Abstract

32. Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13:e1001967.Full text  Abstract

33. Veliziotis I, Roman A, Martiny D, et al. Clinical management of Argentine hemorrhagic gever using ribavirin and favipiravir, Belgium, 2020. Emerg Infect Dis. 2020 Jul;26(7):1562-6.Full text  Abstract

34. Vela E. Animal models, prophylaxis, and therapeutics for arenavirus infections. Viruses. 2012;4:1802-1829.Full text  Abstract

35. Gowen BB, Smee DF, Wong MH, et al. Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters. Antivir Chem Chemother. 2006;17:175-183. Abstract

36. Gowen BB, Barnard DL, Smee DF, et al. Interferon alfacon-1 protects hamsters from lethal pichinde virus infection. Antimicrob Agents Chemother. 2005;49:2378-2386.Full text  Abstract

37. York J, Dai D, Amberg SM, et al. pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J Virol. 2008;82:10932-10939.Full text  Abstract

38. Bolken TC, Laquerre S, Zhang Y, et al. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 2006;69:86-97. Abstract

39. Lavanya M, Cuevas CD, Thomas M, et al. siRNA screen for genes that affect Junín virus entry uncovers voltage-gated calcium channels as a therapeutic target. Sci Transl Med. 2013;5:204ra131.Full text  Abstract

40. Amanat F, Duehr J, Huang C, et al. Monoclonal antibodies with neutralizing activity and Fc-effector functions against the Machupo virus glycoprotein. J Virol. 2020 Feb 14;94(5):e01741-19.Full text  Abstract

41. Pan X, Wu Y, Wang W, et al. Novel neutralizing monoclonal antibodies against Junin virus. Antiviral Res. 2018 Aug;156:21-8. Abstract

42. Zeitlin L, Geisbert JB, Deer DJ, et al. Monoclonal antibody therapy for Junin virus infection. Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63.Full text  Abstract

43. Mapp Biopharmaceutical. LeafBio announces conclusion of ZMapp™ clinical trial. February 2016 [internet publication].Full text

44. Kolokoltsova OA, Yun NE, Paessler S. Reactive astrogliosis in response to hemorrhagic fever virus: microarray profile of Junin virus-infected human astrocytes. Virol J. 2014;11:126.Full text  Abstract

45. McLay L, Liang Y, Ly H. Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections. J Gen Virol. 2014;95:1-15.Full text  Abstract

46. Enría DA, Damilano AJ, Briggiler AM, et al. Sindrome neurologico tardio en enfermos de fiebre hemorrágica Argentina tratados con plasma immune. Medicina (Buenos Aires). 1985;45:615-620.

47. Melcon MO, Herskovits E. Complicaciones neurologicas tardias de la fiebre hemorragica argentina. Medicina (Buenos Aires). 1981;41:137-145.

48. Briggiler AM, Enria DA, Feuillade MR, et al. Contagio interhumano e infeccion inaparente por virus Junin in matrimonios del area endemica de fiebre hemorragica Argentina. Medicina (Buenos Aires). 1987;47:565.

49. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 1979;2:1216-1217. Abstract

50. Hadi CM, Goba A, Khan SH, et al. Ribavirin for Lassa fever postexposure prophylaxis. Emerg Infect Dis. 2010;16:2009-2011.Full text  Abstract

Use of this content is subject to our disclaimer